Perioperative durvalumab improved survival in phase 3 gastric cancer trial
-
October 8
At three years, 69% of patients assigned to durvalumab plus chemotherapy were alive vs. 62% of those assigned to placebo plus chemotherapy.
BROWSE BY TOPICS
Substance use disorders in gastroenterology and hepatology: A practical guide for the general gastroenterologist
-
August 3
-
by Isabelle S. Byers, MD, Michelle Russin, MD, Sasha Deutsch-Link, MD, MSCR
GI and liver complications often bring these patients in first, and the authors say gastroenterologists are well placed to screen and treat.
Bridging the rural divide: Building a motility center in a critical access hospital
-
August 3
-
by Amber Charoen, MD, W. Michael McDonnell, MD, AGAF
“If large urban centers can run comprehensive motility labs, why can't a critical access hospital?”
Is professional coaching worth it? A practical guide for early-career gastroenterologists
-
August 3
-
by Mariam Naveed, MD, FACG, Kathryn E. Hutchins, MD, FACG
Two program directors on why coaching belongs at the start of a GI career, not after something has already gone wrong.
The Latest
Perioperative durvalumab improved survival in phase 3 gastric cancer trial
-
by Doug Brunk
At three years, 69% of patients assigned to durvalumab plus chemotherapy were alive vs. 62% of those assigned to placebo plus chemotherapy.
Small Talk, Big Topics podcast returns for season 4
-
by AGA
Two new hosts join the new season of the podcast to discuss topics including mentorship of women in GI, providing inclusive care to LGBTQI+ patients, and more.
Ductal extension, cancer risk shape AGA advice on ampullary adenomas
-
by Doug Brunk
Adenomas extending more than 1 cm into a duct should prompt surgical consultation, the expert review suggests, while those with less extension may be managed endoscopically with close surveillance.
GI patients deserve better access to care: Advocacy Day recap
-
by AGA
127 clinicians, researchers, and patient advocates joined us for our annual Advocacy Day.
Depleted gut bacteria may help explain food intolerance in IBD
-
by Doug Brunk
About 85% of patients in remission reported food triggers vs. 33% of people without IBD, and their stool broke down dairy proteins less efficiently.
Esophagus
Liver
Small bowel
Stomach
Obesity
Alcohol-related liver disease
Biliary tract cancer
Colorectal cancer
Esophageal cancer
Liver cancer
Celiac disease
Diarrhea and constipation
Diet and nutrition
Eosinophilic GI diseases
Eosinophilic esophagitis
Hepatic encephalopathy
IBD
Crohn's disease
Ulcerative colitis
IBS
Infections
C. diff
MASLD and MASH
Short bowel syndrome
Pancreatic diseases and conditions
GERD and Barrett’s esophagus
Career & professional development
Diversity, equity, and inclusion
Health, wellness, and burnout
Patient advocacy and equity
Practice management
Coding, coverage, and reimbursement
Technology & innovation
Endoscopy